Aurobindo Pharma Ratios

Aurobindo Pharma Ltd Ratios

The Aurobindo Pharma Ltd Ratios page provides a complete fundamental analysis of Aurobindo Pharma Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Aurobindo Pharma Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Aurobindo Pharma Ltd (NSE: AUROPHARMA, BSE: 524804) is currently trading at ₹1312.50, with a market capitalization of ₹746.82B. As a major player in the Health technology sector and Pharmaceuticals: other industry, Aurobindo Pharma Ltd remains a key stock for fundamental analysis using Aurobindo Pharma Ltd Ratios.

Aurobindo Pharma Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Aurobindo Pharma Ltd P/E ratio currently stands at 19.39, making it one of the most tracked metrics in Aurobindo Pharma Ltd Ratios.

Historically, the Aurobindo Pharma Ltd P/E ratio has shown strong fluctuations:

• 2024: 19.39
• 2023: 20.12
• 2022: 15.75
• 2021: 14.80
• 2020: 9.68

The decline in Aurobindo Pharma Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Aurobindo Pharma Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.06.

Historical P/B trend:

• 2024: 2.06
• 2023: 2.14
• 2022: 1.13
• 2021: 1.59

Aurobindo Pharma Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Aurobindo Pharma Ltd P/S ratio currently stands at 2.15, an important part of Aurobindo Pharma Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 2.15
• 2023: 2.22
• 2022: 1.23
• 2021: 1.67

A stable or declining Aurobindo Pharma Ltd P/S ratio indicates cautious market sentiment.

Aurobindo Pharma Ltd Price to Cash Flow Ratio (P/CF)

The Aurobindo Pharma Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 17.55.

Historical Aurobindo Pharma Ltd Price to Cash Flow Ratio:

• 2024: 17.55
• 2023: 25.90
• 2022: 12.53
• 2021: 7.80
• 2020: 15.65

The declining Aurobindo Pharma Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Aurobindo Pharma Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Aurobindo Pharma Ltd EV currently stands at ₹676.16B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 676.16B
• 2023: 641.62B
• 2022: 294.15B
• 2021: 379.05B

Aurobindo Pharma Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Aurobindo Pharma Ltd EV/EBITDA ratio is currently 10.49, a key metric in Aurobindo Pharma Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 10.49
• 2023: 11.23
• 2022: 7.70
• 2021: 8.51

Stable Aurobindo Pharma Ltd EV/EBITDA indicates balanced valuation.

Aurobindo Pharma Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Aurobindo Pharma Ltd D/E ratio is currently 0.25, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.25
• 2023: 0.22
• 2022: 0.20
• 2021: 0.13

Aurobindo Pharma Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Aurobindo Pharma Ltd ROE currently stands at 11.16%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 11.16
• 2023: 11.20
• 2022: 7.50
• 2021: 11.39

Aurobindo Pharma Ltd maintains stable profitability levels.

Aurobindo Pharma Ltd Ratios Analysis Summary

The Aurobindo Pharma Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Aurobindo Pharma Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Aurobindo Pharma Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.